Chelsea Therapeutics Presents Efficacy and Safety Data for NORTHERA

(June 12, 2014) – Chelsea Therapeutics presented an integrated analysis of data from two pivotal multicenter, placebo-controlled, randomized clinical trials showing that NORTHERA™ (droxidopa) had demonstrated an acceptable safety profile and demonstrated a statistically significant difference in efficacy compared to placebo for improving the symptoms of neurogenic orthostatic hypotension (NOH) in a population comprised chiefly of patients with Parkinson's Disease (PD). The results were presented at the 18th International Congress of Parkinson's Disease and Movement Disorders (MDS) in Stockholm, Sweden, June 8-12, 2014. Read more…


Click for a printer friendly version